logo
logo

Resbiotic Spins Out Pharmaceutical Subsidiary Alveolus Bio, Raises $4.5M Seed Funding And Launches First Consumer Health Product

Oct 26, 2021•over 3 years ago

Amount Raised

$4.5 Million

Round Type

seed

Birmingham

Description

Birmingham, Alabama-based biotech startup ResBiotic today announced the spin-out of its drug development arm, Alveolus Bio, and the launch of its first consumer health product, resB® Lung Support. With $4.5M in seed funding, ResBiotic and Alveolus Bio are poised to transform the respiratory care landscape and chart new frontiers for microbiome science.

Company Information

Company

Res Biotic Inc

Location

Birmingham, Alabama, United States

About

ResBiotic is the world's first respiratory probiotics company pioneering science-backed supplements for lung health. Founded and managed by physician scientists, the company is the culmination of decades of research at the intersection of respiratory health and microbiome science. ResBiotic's first product, resB® Lung Support, is a dietary supplement that targets the gut-lung axis. To learn more visit www.resbiotic.com. SOURCE ResBiotic